BERLIN, July 24 (Reuters) - Roche CEO Thomas Schinecker said the Swiss drugmaker was on track to invest in the United States in order to be able to supply the market there.
"What we've done is we've ramped up manufacturing from medicines we were already producing in the United States," said the CEO, adding that additional investments for new products were "very well on track."